Regulatory Comment Comments on Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics Guidance for Industry Share this page The accelerated approval pathway is working as intended: delivering better health to those in dire need. Unfortunately, non-oncology rare diseases are nowhere near that milestone and account for just 23% of all products approved using the accelerated approval pathway. Accelerated Approval